ZIM Laboratories has secured Marketing Authorization from Agenzia Italiana del Farmaco (AIFA), the Italian Medicines Agency, for its anticoagulant product ‘Dabigatran Etexilate’ (75 mg, 110 mg & 150 mg hard capsules), in Italy via DCP to its wholly owned European subsidiary, SIA ZIM Laboratories, Latvia. This authorisation will facilitate faster approvals in other European Union countries as well as the UK and other markets globally resulting in better commercialisation opportunities.
Dabigatran Etexilate Capsules are indicated for the prevention and treatment of thromboembolic disorders, including stroke prevention in patients with non-valvular atrial fibrillation. The product has been developed using the company’s proprietary non-tartaric acid-based formulation design incorporating a novel excipient system and has demonstrated bioequivalence with the innovator product.
ZIM Laboratories manufactures, formulates, and distributes drug delivery systems to develop generic pharmaceutical products.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1777.10 |
| Dr. Reddys Lab | 1266.60 |
| Cipla | 1380.90 |
| Zydus Lifesciences | 1107.00 |
| Lupin | 2270.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: